Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance Strategies
Authors:
- Yan XingYXYan Xing
- Yi-Ju ChiangYCYi-Ju Chiang
- Kate D. CromwellKCKate D. Cromwell
- Merrick I. RossMRMerrick I. Ross
- Jeffrey E. LeeJLJeffrey E. Lee
- Jeffrey E. GershenwaldJGJeffrey E. Gershenwald
- Richard E. RoyalRRRichard E. Royal
- Janice N. CormierJCJanice N. Cormier
- 1 June 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 259 (6) , 1215-1222
Abstract
To guide resource utilization, we aimed to determine the impact of routine surveillance imaging for the detection of melanoma recurrences amenable to surgical resection with curative intent. The National Comprehensive Cancer Network guidelines for melanoma surveillance are largely consensus based. Using single-institution, patient-level data (n = 1600), transition probabilities were calculated for a Markov model simulating the natural history of patients with stage I-III melanoma. As a base estimate, imaging was assumed to detect regional and distant recurrences of which 80% and 20% could be surgically treated with curative intent, respectively. Sensitivity analyses were conducted for all point estimates. For each disease stage, we calculated the number of surgically treatable regional or distant recurrence detected during 5 years per 10,000 patients undergoing computed tomography (CT) or positron emission tomography (PET)/CT scans at 6- or 12-month intervals. The associated positive and negative predictive values and life expectancy were also calculated and compared with clinical examination alone. At 5-year follow-up, CT or PET/CT at 6-month intervals detected surgically treatable regional or distant recurrence in 6.4% of patients with stage I, 18.5% of stage II, and 33.1% of stage III disease; 12-month intervals decreased the rates to 3.0%, 7.9%, and 13.0%, respectively. The high false-positive rates of CT (20%) and PET/CT (9%) resulted in overall low positive predictive values. However, both CT and PET/CT effectively predicted absence of disease. Life-expectancy gains were minimal (≤ 2 months) for all groups. The effectiveness of routine surveillance imaging for detecting treatable melanoma recurrences is limited. Even in patients with stage III disease, only minimal gains in life expectancy were achieved.Keywords
This publication has 38 references indexed in Scilit:
- Increasing Burden of Melanoma in the United StatesJournal of Investigative Dermatology, 2009
- Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanomaThe Journal of Thoracic and Cardiovascular Surgery, 2007
- Current surgical management of melanomaExpert Review of Anticancer Therapy, 2006
- The role of surgery in treatment of stage IV melanomaJournal of Surgical Oncology, 2006
- Cutaneous melanoma and intervention strategies to reduce tumor-related mortality: what we know, what we don't know, and what we think we know that isn't soDermatologic Therapy, 2006
- Cutaneous melanoma: surveillance of patients for recurrence and new primary melanomasDermatologic Therapy, 2005
- Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up StrategyJournal of Clinical Oncology, 2003
- Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanomaCancer, 1999
- A rational approach to melanoma follow-up in patients with primary cutaneous melanomaBritish Journal of Dermatology, 1999
- Follow-up in stage I cutaneous malignant melanoma: An auditClinical Oncology, 1993